Mostly True, But Incomplete: Duke's Stem Cell Trial Found No Significant Benefit for Autism — With One Important Caveat

The claim is mostly true but strips away important context. Duke University did run a rigorous Phase 2 clinical trial on 180 children with autism, and the results, published in JAMA Pediatrics in 2020, showed that cord blood infusion did not significantly improve social communication skills compared to a placebo. On the trial's main measure — the Vineland Adaptive Behavior Scales — the two groups were nearly identical, with the cord blood group improving by 4.3 points and the placebo group by 4.2 points. That is not a meaningful difference.

So where does the 'partially false' verdict come in? The claim flattens a more complicated picture. While the primary endpoint clearly failed, some secondary and exploratory measures showed modest signals worth investigating. The trial also confirmed the treatment was safe. Researchers and independent experts, including those at the Science Media Centre, were careful to say the evidence does not support clinical use — but they did not say the door is entirely closed on future research.

There is also a terminology problem. Popular coverage often uses 'stem cells' loosely, but this trial used umbilical cord blood, a specific source that contains a mix of cell types. That distinction matters because it affects how results can be generalized. Cord blood infusion is not the same as the broader category of stem cell therapies being marketed at private clinics around the world.

The Autism Science Foundation and other watchdog groups have used these results to warn families away from unproven commercial stem cell treatments, which can cost tens of thousands of dollars and carry real risks. The Duke trial was well-designed and adequately powered — meaning it had enough participants to detect a real effect if one existed. Its failure to find one on the primary outcome is meaningful.

This claim spreads in two opposite directions at once: skeptics cite it to dismiss stem cell research entirely, while proponents of alternative therapies cite the secondary signals to argue the treatment works but was unfairly dismissed. Both readings are selective. The honest takeaway is that this specific treatment, in this trial, did not clear the bar — and that is exactly what rigorous science is supposed to tell us.